What makes the present findings particularly interesting is that the benefits observed were not limited to the gut itself but ...

A multi-cohort transcriptomic, genetic, and experimental study identifies the RHBDF2–ADAM17–TNFα axis as a molecular bridge ...

Former Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic ...

U.K. microbiome company Microbiotica has raised £36 million (€43 million), the first close of a Series C round led by the ...

Eli Lilly and Co. LLY on Thursday revealed new data demonstrating that Omvoh (mirikizumab-mrkz) helps patients with moderately to severely active ulcerative colitis (UC) and Crohn’s disease achieve ...

A study presented at ACG reveals low dermatology and cervical cancer screening rates in patients with ulcerative colitis and ...

Thursday, Eli Lilly and Company ( LLY) announced new data analyses showing that, at one year, patients with moderately to severely active ulcerative colitis and Crohn's disease treated with Omvoh ...

Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by ...

RBC kept its GBp 1,975 target on October 13, 2026. GSK stock faces October 28 results after GBP 8.41 billion second-quarter ...

A Cedars-Sinai-led clinical trial found that a once-daily oral medication significantly outperformed placebo in treating adults with moderate to severe ulcerative colitis. The results were published ...

Elective colectomy was associated with a lower mortality risk compared with continuing medical therapy in a nationwide ...

Researchers at Georgia State University identified two metabolite-inspired compounds that showed enhanced anti-inflammatory ...